ASTROGEN

Company History

With years of clinical experience, Astrogen is exploring new horizons in innovative
new drug development field at an unprecedented speed.

2023

2022

SeptemberSigned an MOU with the Dept. of Neurosurgery of Seoul National University Bundang Hospital
Signed an MOU with the Molecular Biology & Phylogeny Lab. (MPL) of the Dept. of Biological Sciences of Pusan National University
AugustSelected as Employment-Friendly Company by Daegu City
Selected as one of BIG3 projects by the Ministry of SMEs and Startups
Designated as Startup Growth Technology Development Project
Received the investment of Bridge 2 (KRW 3 billion)
JuneSigned an MOU with the Value Development and Play Center
MayCompleted observation for the final subject of the phase 2 clinical trial for AST-001
FebruaryReceived the investment of Bridge 1 (KRW 9 billion)

2021

DecemberReceived Presidential Citation for Venture Startup Promotion Merit Award
Certified as Family-Friendly Company by the Ministry of Gender Equality & Family
Collaborated with IKTOS, AI-based new drug development company
NovemberDesignated as Excellent Corporate R&D Center by the Ministry of Science and ICT
OctoberIntroduced Astrogen’s ESG ethical management
SeptemberUploaded the Astrogen ESG Report on the website
Selected as Pre-Star Company by Daegu City
FebruaryPhase 1 Clinical Study Report for AST-001 (CSR)
Enrolled the first trial subject in the phase 2 clinical trial for AST-001

2020

DecemberReceived the investment of Series B (KRW 13 billion)
Received Grand Prize at the Daegu Startup Awards by the Daegu Center for Creative Economy Innovation
Received Minister Award from the Ministry of Trade, Industry and Energy for revitalizing free economic zone
NovemberSelected as the National Representative Innovative Company by the Financial Services Commission
AugustOpened the Astrogen's Pharmaceutical Research Institute (Naju) Office
JulyReceived approval of IND application for phase 2 clinical trial for AST-001
JuneSelected as “Baby Unicorn” company by the Ministry of SMEs and Startups
MayCompleted construction of Astrogen’s new office building
MarchReceived IND for phase 1 clinical trial for AST-001

2019

DecemberStarted construction of Astrogen’s new building and research center
NovemberSelected as the Frontier Venture Company by the Korea Technology Finance Corp. (KIBO)
Selected as A+ Member by the KIBO
AugustReceived the investment of Series A (KRW 5 billion of capital increase)
MayObtained the approval to move into the Daegu-Gyeongbuk Medical Cluster
MarchOpened the Astrogen's Business Development Division (Seoul) office

2018

2017